Thomas Zilli

How do you resign from an academic medical position? I distilled my practical advice into 20 lessons. One lesson: never threaten to leave without another offer. @ASTRO_org #AcademicMedicine #MedEd authors.elsevier.com/a/1nU%7Eu6hRQn… practicalradonc.org/article/S1879-…

💛 𝑾𝒐𝒓𝒌 𝒐𝒇 𝒂𝒓𝒕 💛 #TDF2026

Can we safely put more radiation where the tumor is—and less where it isn't? How to focal boost in prostate cancer radiotherapy☢️: ESTRO clinical practice consensus recommendations This @ESTRO_RT recommendation reviews evidence supporting focal dose escalation in #ProstateCancer radiotherapy. While whole-gland dose escalation can improve📈 biochemical progression-free survival (bPFS), it may increase toxicity. The phase III FLAME trial demonstrated that isotolerated focal boosting of intraprostatic tumors improves bPFS without significantly increasing side effects. The guideline 📖provides practical, evidence-based recommendations for implementing focal boosting using external beam radiotherapy or brachytherapy in routine clinical practice. @TylerSbrt @BarbaraJereczek @Simon_Spohn @alison_tree @PietersBradley @tobbel_swe @OncoAlert 🚨 #LPCCC26 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists 👉Link to Article in First Comment

“How to’ do SBRT in prostate cancer” consensus recommendations is to define minimum requirements, common practices and additional options for prostate SBRT based on scientific evidence, expert opinion and consensus. @RO_GreenJournal @ESTRO_RT Read it 👉 thegreenjournal.com/article/S0167-…

🏆 REMCO EVENEPOEL 🇧🇪 EXPLOSE TADEJ POGACAR AU PLATEAU DE SOLAISON !!! 🤯🤯 C'EST PAS VRAI MAIS QUE SE PASSE-T-IL ??? 👑🤩 ON VIT UN REVE LÀ 🥹 #TDF2026

⚡️ In MIBC, radical cystectomy remains the standard — but not every patient chooses it. In the ICI/ADC era, trimodality therapy is gaining ground as an individualized alternative. How do we integrate it alongside perioperative EV + pembrolizumab? #f0005" target="_blank" rel="nofollow noopener">euoncology.europeanurology.com/article/S2588-… #BladderCancer @EurUrolOncol

Collaborate with leading experts and drive key radiotherapy initiatives forward. ESTRO Focus Groups are recruiting: ✅ Positioning & Immobilisation (RadOnc) ✅ AI (Non-Medical Physics) ✅ CNS, Dosimetry, SBRT, Skin, SFRT, Lung, Urology 👉 Apply by 14 Aug: bit.ly/4vloV2I

Online now: Systemic therapy, gastrectomy, cytoreductive surgery, and HIPEC versus systemic therapy alone for #gastriccancer with limited peritoneal metastases (PERISCOPE II): results of a phase 3 trial after an unplanned commissioned interim analysis thelancet.com/journals/lanon…

@Urodoc46 @Adam_Weiner535 @JAMAOnc In this trial we included only LR patients refusing AS (1st choice)

@Adam_Weiner535 @JAMAOnc Why are they treating low risk?

🚨 ONE-SHOT prostate SBRT: Can we treat localized prostate cancer in 1 fraction?☢️ @JAMAOnc Phase 1/2 multicenter trial 👥 45 men, low/intermediate-risk PCa 🎯 19 Gy single-fraction urethra-sparing SBRT 📍 Intrafraction motion control Results: ✅ 3-yr bRFS: 92.9% ✅ Grade 2 GU toxicity: 9.8% ✅ Grade 2 GI toxicity: 4.9% ⚠️ 1 grade 3 proctitis ⚠️ Erectile dysfunction increased over time 🔑: 1-and-done prostate SBRT looks feasible in carefully selected patients… …but 5-fraction SBRT remains the benchmark until larger cohorts + longer follow-up confirm durability. 🔬 🔗shorturl.at/vGDDv @PCFnews @PCF_Science @UrologyTimes @urotoday

How to focal boost in #ProstateCancer radiotherapy: ESTRO clinical practice consensus recommendations. 👉 Read the article in open access in the #GreenJournal: bit.ly/4vAATpv #radiotherapy #guidelines #RadiationOncology

1/ New in Radiotherapy & Oncology: ESTRO consensus recommendations on how to focal boost the intraprostatic tumour in prostate cancer. The practical question: now that FLAME is positive, who gets a boost, how do we contour it, and what dose do we prescribe? Why it matters: focal boosting is about to become a lot more common.

Controversial then, settled now: I remember when PSMA PET/CT was not recommended - concern of Will Roger's "Stage Migration". Now, 95% of the international panel agreed that PSMA PET/CT should be the staging tool in high-risk prostate cancer (strong consensus), and 85% would not substitute whole-body MRI for it. From investigational to unanimous #ProPSMA The flip side is just as important. Zero of 18 questions on monitoring metastatic disease reached consensus. More evidence is needed. @APCCC_Lugano Diagnostics 2025 is out in @EUplatinum: authors.elsevier.com/sd/article/S03…

Call for Young Reviewers – #EMUC26 Abstract Review 📢 You are: ✅ 38 years or younger ✅ Have an interest in uro-oncology ✅ Are available to review abstracts during August 2026 (approximately a 3-week review period) Find out more👉 eanm.org/news/emuc26-ca…

🚨 🚨🚨New Editorial in @EurUrolOncol ! #PROTEUS trial: a landmark study, but are we ready for treatment intensification in high-risk PCa? We discuss the evidence, unanswered questions, biomarkers, and the evolving role of multimodal care. sciencedirect.com/science/articl…

Applications are open for the 3rd cohort of the Certificate of Advanced Studies in Prostate Cancer (CAS-Pr), in collaboration with @USI_university. Deepen your clinical and scientific expertise through a 16-month part-time blended programme (6 online modules + 3 in-person seminars at PROSCA, APCCC, and LTC). Scholarship opportunity: The ESO College offers full tuition coverage for one selected Fellow or Graduate. ⚠️ Deadline: 15 August 2026 👉 Apply now: bit.ly/CASProstate

Important study. 🔑 quote below. We cannot wish a surrogate endpoint into existence, sadly. “Higher pCR rates often accompanied better survival within studies. But treatment-induced improvements in pCR did not reliably predict treatment.”

Probably is not a question of dose, but radiobiology. SHERBET data suggest the same hypothesis doi.org/10.1001/jamane…

Single-fraction SBRT for localized prostate cancer continues to push the boundaries. Multicenter phase 1/2 trial (45 pts), single 19-Gy fraction:
✅ 3-year bRFS: 92.9%
✅ Grade 2+ GU AE: <10%
✅ Grade 2+ GI AE: <5%

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer jamanetwork.com/journals/jamao… @Mat_Guc @CiroFranzese1 @alongi_filippo @Achard_Verane

In #rectal & #analcancer, it’s all about personalisation. #ESTRO26 showcased a fast-moving field—from organ preservation to the landmark PLATO trials. Technical precision is now inseparable from patient experience. 👉 bit.ly/43Gyq12 #Radonc #Radiotherapy @Pier_Franco_MD